BR0110364A - Administração intratecal de rituximab para tratamento de linfomas do sistema nervoso central - Google Patents

Administração intratecal de rituximab para tratamento de linfomas do sistema nervoso central

Info

Publication number
BR0110364A
BR0110364A BR0110364-4A BR0110364A BR0110364A BR 0110364 A BR0110364 A BR 0110364A BR 0110364 A BR0110364 A BR 0110364A BR 0110364 A BR0110364 A BR 0110364A
Authority
BR
Brazil
Prior art keywords
antibodies
rituximab
nervous system
central nervous
treatment
Prior art date
Application number
BR0110364-4A
Other languages
English (en)
Inventor
Antonio J Gillo-Lopez
Original Assignee
Idec Pharma Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Idec Pharma Corp filed Critical Idec Pharma Corp
Publication of BR0110364A publication Critical patent/BR0110364A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1027—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against receptors, cell-surface antigens or cell-surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Optics & Photonics (AREA)
  • Biomedical Technology (AREA)
  • Physics & Mathematics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

"ADMINISTRAçãO INTRATECAL DE RITUXIMAB PARA TRATAMENTO DE LINFOMAS DO SISTEMA NERVOSO CENTRAL". A presente invenção descreve métodos de uso de anticorpos anticélula B, de preferência, anticorpos anti-CD20, e com mais preferência Rituximab, para tratar linfomas de célula B do cérebro, especialmente linfomas do sistema nervoso central primário (PCNSL) e prevenir recidiva da meninge. Os anticorpos podem ser administrados intratecalmente sozinhos ou em combinação com outros quimioterapêuticos, tal como metotrexato, ou outros anticorpos anticélula B para tratar PCNSL, em ambos pacientes imunocomprometidos e não-imunocomprometidos. Esses anticorpos podem ser também usados para diagnosticar pacientes com linfoma do CNS, especialmente em pacientes imunocomprometidos.
BR0110364-4A 2000-04-25 2001-04-25 Administração intratecal de rituximab para tratamento de linfomas do sistema nervoso central BR0110364A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US19936500P 2000-04-25 2000-04-25
PCT/US2001/013264 WO2001080884A1 (en) 2000-04-25 2001-04-25 Intrathecal administration of rituximab for treatment of central nervous system lymphomas

Publications (1)

Publication Number Publication Date
BR0110364A true BR0110364A (pt) 2003-12-30

Family

ID=22737212

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0110364-4A BR0110364A (pt) 2000-04-25 2001-04-25 Administração intratecal de rituximab para tratamento de linfomas do sistema nervoso central

Country Status (11)

Country Link
US (1) US20020009444A1 (pt)
EP (1) EP1286692A4 (pt)
JP (1) JP2003531178A (pt)
KR (1) KR20030016250A (pt)
CN (2) CN1437478A (pt)
AU (2) AU2001259142C1 (pt)
BR (1) BR0110364A (pt)
CA (1) CA2405632A1 (pt)
MX (1) MXPA02010507A (pt)
WO (1) WO2001080884A1 (pt)
ZA (1) ZA200208627B (pt)

Families Citing this family (116)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7744877B2 (en) * 1992-11-13 2010-06-29 Biogen Idec Inc. Expression and use of anti-CD20 Antibodies
ES2091684T3 (es) * 1992-11-13 1996-11-01 Idec Pharma Corp Aplicacion terapeutica de anticuerpos quimericos y radiomarcados contra el antigeno de diferenciacion restringida de los linfocitos b humanos para el tratamiento del linfoma de las celulas b.
EP1112084B2 (en) 1998-08-11 2012-04-25 Biogen Idec Inc. Combination therapies for b-cell lymphomas comprising administration of anti-cd20 antibody
KR20010103655A (ko) * 1998-11-09 2001-11-23 케네쓰 제이. 울코트 키메라 항-ｃｄ２０항체를 이용한 순환성 종양세포와관련된 혈액학적 악성종양의 치료법
KR20010099788A (ko) * 1998-11-09 2001-11-09 케네쓰 제이. 울코트 Ｂｍｔ 또는 ｐｂｓｃ 이식을 받은 환자의 키메라항-ｃｄ２０ 항체 치료법
AU777970C (en) * 1999-05-07 2006-08-17 F. Hoffman-La Roche Ag Treatment of autoimmune diseases with antagonists which bind to B cell surface markers
IL147547A0 (en) * 1999-07-12 2002-08-14 Genentech Inc Blocking immune response to a foreign antigen using an antagonist which binds to cd20
US8557244B1 (en) 1999-08-11 2013-10-15 Biogen Idec Inc. Treatment of aggressive non-Hodgkins lymphoma with anti-CD20 antibody
DE60028830T2 (de) * 2000-02-16 2007-01-18 Genentech, Inc., South San Francisco Anti-april antikörper und hybridomazellen
CA2422076A1 (en) * 2000-09-18 2002-03-21 Idec Pharmaceutical Corporation Combination therapy for treatment of autoimmune diseases using b cell depleting/immunoregulatory antibody combination
US20030133939A1 (en) 2001-01-17 2003-07-17 Genecraft, Inc. Binding domain-immunoglobulin fusion proteins
US7754208B2 (en) 2001-01-17 2010-07-13 Trubion Pharmaceuticals, Inc. Binding domain-immunoglobulin fusion proteins
US7829084B2 (en) * 2001-01-17 2010-11-09 Trubion Pharmaceuticals, Inc. Binding constructs and methods for use thereof
US6890355B2 (en) 2001-04-02 2005-05-10 Gary K. Michelson Artificial contoured spinal fusion implants made of a material other than bone
MXPA04001050A (es) * 2001-08-03 2004-07-08 Genentech Inc Polipeptidos tacis y br3 y usos de los mismos.
US8287864B2 (en) 2002-02-14 2012-10-16 Immunomedics, Inc. Structural variants of antibodies for improved therapeutic characteristics
CN101914158A (zh) * 2002-02-14 2010-12-15 免疫医疗公司 抗cd 20抗体及其融合蛋白和使用方法
CN1692127A (zh) * 2002-07-25 2005-11-02 健泰科生物技术公司 Taci抗体及其用途
PT3284753T (pt) 2002-10-17 2020-05-04 Genmab As Anticorpos monoclonais humanos contra cd20 para utilização no tratamento da esclerose múltipla
RU2005122033A (ru) * 2002-12-13 2006-01-27 Митра Медикал Текнолоджи Аб (Se) Направленные противолимфомные средства с эффекторной и аффиновой функциями, связанные трехфункциональным реагентом
EP3263596A1 (en) * 2002-12-16 2018-01-03 Genentech, Inc. Immunoglobulin variants and uses thereof
AU2003303521A1 (en) * 2002-12-31 2004-07-29 Genta Incorporated Combination of gallium compounds with nonchemotherapeutic anticancer agents in the treatment of neoplasia
WO2004079013A1 (en) * 2003-03-03 2004-09-16 Arizona Board Of Regents On Behalf Of The University Of Arizona Ecto-5’-nucleotidase (cd73) used in the diagnosis and the treatment of pancreatic cancer
CA2519870A1 (en) * 2003-04-09 2004-10-28 Genentech, Inc. Use of rituximab intravenous compositions to treat rheumatoid arthritis
JP5416338B2 (ja) * 2003-05-09 2014-02-12 デューク ユニバーシティ Ｃｄ２０特異的抗体およびその使用方法
US20050163775A1 (en) * 2003-06-05 2005-07-28 Genentech, Inc. Combination therapy for B cell disorders
CA2526402A1 (en) * 2003-06-05 2005-01-20 Genentech, Inc. Blys antagonists and uses thereof
AU2004255216B2 (en) * 2003-07-01 2010-08-19 Immunomedics, Inc. Multivalent carriers of bi-specific antibodies
CN1860367B (zh) * 2003-07-29 2010-05-26 健泰科生物技术公司 人抗cd20抗体的测定法及其用途
JP2007504138A (ja) * 2003-08-29 2007-03-01 ジェネンテック・インコーポレーテッド 眼疾患の治療法
DK2348051T3 (en) 2003-11-05 2019-03-18 Roche Glycart Ag CD20 antibodies with increased fc receptor binding affinity and effector function
KR20060107555A (ko) * 2003-12-19 2006-10-13 제넨테크, 인크. 이식 거부에서 ｃｄ20의 검출
CA2549122A1 (en) * 2003-12-19 2005-07-07 Genentech, Inc. Detection of cd20 in therapy of autoimmune diseases
KR20070012408A (ko) * 2004-04-16 2007-01-25 제넨테크, 인크. Ｂ 세포 고갈을 증대시키는 방법
JP5848861B2 (ja) 2004-04-20 2016-01-27 ジェンマブ エー／エスＧｅｎｍａｂ Ａ／Ｓ Ｃｄ２０に対するヒトモノクローナル抗体
SG175659A1 (en) * 2004-05-05 2011-11-28 Genentech Inc Preventing autoimmune disease by using an anti-cd20 antibody
DOP2005000108A (es) * 2004-06-04 2007-06-15 Genentech Inc Method for treating lupus
CN106075435A (zh) * 2004-06-04 2016-11-09 健泰科生物技术公司 用于治疗多发性硬化的方法
BRPI0513100A (pt) * 2004-07-22 2007-10-23 Genentech Inc métodos de tratamento da sìndrome de sjÍgren e artigos manufaturados
BR122018016031B8 (pt) 2004-08-04 2021-07-27 Applied Molecular Evolution Inc processo para produzir um anticorpo monoclonal variante com resposta de adcc realçada
AU2005294666A1 (en) * 2004-10-05 2006-04-20 Genentech, Inc. Method for treating vasculitis
BRPI0606108A2 (pt) * 2005-01-13 2009-06-02 Genentech Inc processo de tratamento
DOP2006000029A (es) * 2005-02-07 2006-08-15 Genentech Inc Antibody variants and uses thereof. (variantes de un anticuerpo y usos de las mismas)
EP2548575A1 (en) * 2005-02-15 2013-01-23 Duke University Anti-CD19 antibodies that mediate ADCC for use in treating autoimmune diseases
US8444973B2 (en) 2005-02-15 2013-05-21 Duke University Anti-CD19 antibodies and uses in B cell disorders
TW200714289A (en) * 2005-02-28 2007-04-16 Genentech Inc Treatment of bone disorders
US8475794B2 (en) 2005-04-06 2013-07-02 Ibc Pharmaceuticals, Inc. Combination therapy with anti-CD74 antibodies provides enhanced toxicity to malignancies, Autoimmune disease and other diseases
US8349332B2 (en) 2005-04-06 2013-01-08 Ibc Pharmaceuticals, Inc. Multiple signaling pathways induced by hexavalent, monospecific and bispecific antibodies for enhanced toxicity to B-cell lymphomas and other diseases
AR053579A1 (es) * 2005-04-15 2007-05-09 Genentech Inc Tratamiento de la enfermedad inflamatoria intestinal (eii)
CA2608751A1 (en) * 2005-05-18 2006-11-23 Novartis Ag Methods for diagnosis and treatment of proliferative disorders mediated by cd40 signaling
PL1889065T3 (pl) 2005-05-18 2013-12-31 Novartis Ag Metody diagnostyki i leczenia chorób posiadających składnik autoimmunologiczny i/lub zapalny
ATE460672T1 (de) * 2005-05-20 2010-03-15 Genentech Inc Vorbehandlung einer biologischen probe aus einem individuum mit autoimmunkrankheit
US8293716B2 (en) 2005-05-26 2012-10-23 Ramot At Tel Aviv University Ltd. Method of treating cancer by modulation of mortalin
WO2007014278A2 (en) 2005-07-25 2007-02-01 Trubion Pharmaceuticals, Inc. B-cell reduction using cd37-specific and cd20-specific binding molecules
CN101267836A (zh) 2005-07-25 2008-09-17 特鲁比昂药品公司 单剂量cd20特异性结合分子的用途
US20080279850A1 (en) * 2005-07-25 2008-11-13 Trubion Pharmaceuticals, Inc. B-Cell Reduction Using CD37-Specific and CD20-Specific Binding Molecules
MY149159A (en) 2005-11-15 2013-07-31 Hoffmann La Roche Method for treating joint damage
US9726673B2 (en) * 2005-11-23 2017-08-08 Genentech, Inc. Methods and compositions related to B cell assays
RS53168B (en) 2006-05-30 2014-06-30 Genentech Inc. Antibodies and Immunoconjugates and Their Use
WO2007146968A2 (en) * 2006-06-12 2007-12-21 Trubion Pharmaceuticals, Inc. Single-chain multivalent binding proteins with effector function
JP2009543579A (ja) 2006-07-19 2009-12-10 ザ・トラスティーズ・オブ・ザ・ユニバーシティ・オブ・ペンシルバニア 抗炎症反応のための標的としてのＷＳＸ−１／ｐ２８
WO2008032324A2 (en) * 2006-09-14 2008-03-20 Ramot At Tel Aviv University Ltd. Combination therapy for tumoral disease treatment
US9382327B2 (en) * 2006-10-10 2016-07-05 Vaccinex, Inc. Anti-CD20 antibodies and methods of use
SG10202005450PA (en) 2007-07-09 2020-07-29 Genentech Inc Prevention of disulfide bond reduction during recombinant production of polypeptides
US8470793B2 (en) 2007-09-25 2013-06-25 Ramot At Tel-Aviv University Ltd. Down-regulation of mortalin by siRNA
WO2009052293A1 (en) 2007-10-16 2009-04-23 Zymogenetics, Inc. Combination of blys inhibition and anti-cd 20 agents for treatment of autoimmune disease
US7914785B2 (en) 2008-01-02 2011-03-29 Bergen Teknologieverforing As B-cell depleting agents, like anti-CD20 antibodies or fragments thereof for the treatment of chronic fatigue syndrome
EP2077281A1 (en) 2008-01-02 2009-07-08 Bergen Teknologioverforing AS Anti-CD20 antibodies or fragments thereof for the treatment of chronic fatigue syndrome
CN102014959B (zh) * 2008-03-10 2016-01-20 康奈尔大学 血脑屏障通透性的调节
CN102099377A (zh) 2008-04-11 2011-06-15 新兴产品开发西雅图有限公司 Cd37免疫治疗剂及其与双功能化学治疗剂的联合
TW201016233A (en) * 2008-07-15 2010-05-01 Genentech Inc Methods of treating autoimmune diseases using CD4 antibodies
UA108735C2 (uk) 2008-07-21 2015-06-10 Структурні варіанти антитіл для покращення терапевтичних характеристик
TW201014605A (en) * 2008-09-16 2010-04-16 Genentech Inc Methods for treating progressive multiple sclerosis
JP2012508774A (ja) * 2008-11-13 2012-04-12 エマージェント プロダクト デベロップメント シアトル， エルエルシー Ｃｄ３７免疫治療薬併用療法およびその使用
WO2010074724A1 (en) * 2008-12-22 2010-07-01 Millennium Pharmaceuticals, Inc. Combination of aurora kinase inhibitors and anti-cd20 antibodies
WO2010075249A2 (en) 2008-12-22 2010-07-01 Genentech, Inc. A method for treating rheumatoid arthritis with b-cell antagonists
US20110142836A1 (en) * 2009-01-02 2011-06-16 Olav Mella B-cell depleting agents for the treatment of chronic fatigue syndrome
CA2753285A1 (en) * 2009-03-12 2010-09-16 Genentech, Inc. Combinations of phosphoinositide 3-kinase inhibitor compounds and chemotherapeutic agents for the treatment of hematopoietic malignancies
US20120329709A1 (en) * 2009-05-26 2012-12-27 Brian Edward Collins Production of glycoproteins
US20120277165A1 (en) * 2009-06-05 2012-11-01 Collins Brian E Methods of modulating fucosylation of glycoproteins
RU2639288C2 (ru) 2009-08-11 2017-12-20 Дженентек, Инк. Получение белков в культуральных средах без глутамина
AR078161A1 (es) 2009-09-11 2011-10-19 Hoffmann La Roche Formulaciones farmaceuticas muy concentradas de un anticuerpo anti cd20. uso de la formulacion. metodo de tratamiento.
NO331080B1 (no) * 2010-01-29 2011-09-26 Nordic Nanovector As Radioimmunkonjugater, farmasøytiske sammensetninger og kit omfattende det samme og anvendelse derav
TW201129384A (en) 2010-02-10 2011-09-01 Immunogen Inc CD20 antibodies and uses thereof
KR101010256B1 (ko) * 2010-03-17 2011-01-21 (주)이레이앤엘 데크로드 장치
ES2602108T3 (es) 2010-04-07 2017-02-17 Momenta Pharmaceuticals, Inc. Método para cuantificar glicoformas que contienen alta manosa
CN103782168B (zh) 2011-03-12 2016-03-16 动量制药公司 在糖蛋白产品中包含n-乙酰己糖胺的n-聚醣
RU2016127812A (ru) 2011-03-31 2018-12-06 Дженентек, Инк. Способы введения антагонистов интегрина бета7
WO2013181575A2 (en) 2012-06-01 2013-12-05 Momenta Pharmaceuticals, Inc. Methods related to denosumab
ES2738305T3 (es) 2012-10-05 2020-01-21 Hoffmann La Roche Procedimientos para diagnosticar y tratar enfermedades inflamatorias intestinales
WO2014149067A1 (en) 2013-03-15 2014-09-25 Momenta Pharmaceuticals, Inc. Methods related to ctla4-fc fusion proteins
SG11201507759WA (en) * 2013-04-02 2015-10-29 Celgene Corp Methods and compositions using 4-amino-2-(2,6-dioxo-piperidine-3-yl)-isoindoline-1,3-dione for treatment and management of central nervous system cancers
WO2014186310A1 (en) 2013-05-13 2014-11-20 Momenta Pharmaceuticals, Inc. Methods for the treatment of neurodegeneration
KR20160099081A (ko) * 2013-07-26 2016-08-19 업데이트 파마 인코포레이트 비산트렌의 치료 효과 개선용 조합 방법
EP3058084A4 (en) 2013-10-16 2017-07-05 Momenta Pharmaceuticals, Inc. Sialylated glycoproteins
KR20220065091A (ko) 2014-03-27 2022-05-19 제넨테크, 인크. 염증성 장 질환의 진단 및 치료 방법
EP3303373B1 (en) 2015-05-30 2020-04-08 Molecular Templates, Inc. De-immunized, shiga toxin a subunit scaffolds and cell-targeting molecules comprising the same
BR112017024610A2 (pt) 2015-06-24 2018-07-31 F. Hoffmann-La Roche Ag anticorpos para receptor antitransferrina com afinidade especificada
US11028155B2 (en) 2015-09-11 2021-06-08 Nascent Biotech, Inc. Enhanced delivery of drugs to the brain
CN108367004B (zh) 2015-09-21 2022-09-13 阿帕特夫研究和发展有限公司 Cd3结合多肽
AR106189A1 (es) 2015-10-02 2017-12-20 Hoffmann La Roche ANTICUERPOS BIESPECÍFICOS CONTRA EL A-b HUMANO Y EL RECEPTOR DE TRANSFERRINA HUMANO Y MÉTODOS DE USO
CN114031689A (zh) 2015-10-02 2022-02-11 豪夫迈·罗氏有限公司 双特异性抗人cd20/人转铁蛋白受体抗体及使用方法
JP2018529747A (ja) 2015-10-06 2018-10-11 ジェネンテック， インコーポレイテッド 多発性硬化症を治療するための方法
WO2019168847A1 (en) 2018-02-27 2019-09-06 Incyte Corporation Imidazopyrimidines and triazolopyrimidines as a2a / a2b inhibitors
EP3762421A2 (en) 2018-03-09 2021-01-13 Agenus Inc. Anti-cd73 antibodies and methods of use thereof
CA3100731A1 (en) 2018-05-18 2019-11-21 Incyte Corporation Fused pyrimidine derivatives as a2a / a2b inhibitors
EP3886824A1 (en) * 2018-11-30 2021-10-06 Fondazione Centro San Raffaele Combined treatment of primary central nervous system lymphoma
TWI829857B (zh) 2019-01-29 2024-01-21 美商英塞特公司 作為a2a / a2b抑制劑之吡唑并吡啶及三唑并吡啶
AU2020342778A1 (en) 2019-09-06 2022-03-31 Les Laboratoires Servier Anti-CD73 antibodies
KR20220137013A (ko) 2020-01-03 2022-10-11 인사이트 코포레이션 Cd73 억제제 및 a2a/a2b 아데노신 수용체 억제제 병용 요법
AU2021411952A1 (en) 2020-12-29 2023-08-10 Incyte Corporation Combination therapy comprising a2a/a2b inhibitors, pd-1/pd-l1 inhibitors, and anti-cd73 antibodies
WO2022167052A1 (en) 2021-02-08 2022-08-11 Y-Mabs Therapeutics, Inc. Use of ascorbic acid as stabilizing agent for anti b7-h3 antibodies
CN113436721B (zh) * 2021-06-18 2023-01-17 广州医科大学附属肿瘤医院 原发性中枢神经系统淋巴瘤预后模型的建立方法及应用
US11492394B1 (en) 2021-10-29 2022-11-08 Nascent Biotech, Inc. Kits and containers for treating vimentin expressing tumors
WO2023146931A2 (en) * 2022-01-25 2023-08-03 Plus Therapeutics, Inc. Radiolabeled liposomes and methods of use for treating leptomeningeal metastases
WO2023241659A1 (en) * 2022-06-16 2023-12-21 Beigene, Ltd. Methods of treating lymphoma using anti-tigit antibodies

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4665077A (en) * 1979-03-19 1987-05-12 The Upjohn Company Method for treating rejection of organ or skin grafts with 6-aryl pyrimidine compounds
US4460559A (en) * 1980-03-03 1984-07-17 Goldenberg Milton David Tumor localization and therapy with labeled antibodies specific to intracellular tumor-associated markers
US4348376A (en) * 1980-03-03 1982-09-07 Goldenberg Milton David Tumor localization and therapy with labeled anti-CEA antibody
US4472509A (en) * 1982-06-07 1984-09-18 Gansow Otto A Metal chelate conjugated monoclonal antibodies
US4454106A (en) * 1982-06-07 1984-06-12 Gansow Otto A Use of metal chelate conjugated monoclonal antibodies
US4816567A (en) * 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4831175A (en) * 1986-09-05 1989-05-16 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Backbone polysubstituted chelates for forming a metal chelate-protein conjugate
IL85035A0 (en) * 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
IL85746A (en) * 1988-03-15 1994-05-30 Yeda Res & Dev Preparations comprising t-lymphocyte cells treated with 8-methoxypsoralen or cell membranes separated therefrom for preventing or treating autoimmune diseases
US5116964A (en) * 1989-02-23 1992-05-26 Genentech, Inc. Hybrid immunoglobulins
US5182107A (en) * 1989-09-07 1993-01-26 Alkermes, Inc. Transferrin receptor specific antibody-neuropharmaceutical or diagnostic agent conjugates
WO1992022653A1 (en) * 1991-06-14 1992-12-23 Genentech, Inc. Method for making humanized antibodies
IE922437A1 (en) * 1991-07-25 1993-01-27 Idec Pharma Corp Recombinant antibodies for human therapy
US5874082A (en) * 1992-07-09 1999-02-23 Chiron Corporation Humanized anti-CD40 monoclonal antibodies and fragments capable of blocking B cell proliferation
US5397703A (en) * 1992-07-09 1995-03-14 Cetus Oncology Corporation Method for generation of antibodies to cell surface molecules
ES2091684T3 (es) * 1992-11-13 1996-11-01 Idec Pharma Corp Aplicacion terapeutica de anticuerpos quimericos y radiomarcados contra el antigeno de diferenciacion restringida de los linfocitos b humanos para el tratamiento del linfoma de las celulas b.
US5736137A (en) * 1992-11-13 1998-04-07 Idec Pharmaceuticals Corporation Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma
PT721469E (pt) * 1993-09-02 2000-04-28 Dartmouth College Anticorpos anti-gp39 e suas utilizacoes2
US5595721A (en) * 1993-09-16 1997-01-21 Coulter Pharmaceutical, Inc. Radioimmunotherapy of lymphoma using anti-CD20
DK0724456T3 (da) * 1993-10-01 2004-04-13 Immunex Corp CD40-Antistoffer
US5874085A (en) * 1993-11-10 1999-02-23 Henry M. Jackson Foundation For The Advancement Of Military Medicine Vaccine for enhanced production of IgA antibodies
CA2179196A1 (en) * 1993-12-23 1995-06-29 Richard J. Armitage Method of preventing or treating disease characterized by neoplastic cells expressing cd40
US5716614A (en) * 1994-08-05 1998-02-10 Molecular/Structural Biotechnologies, Inc. Method for delivering active agents to mammalian brains in a complex with eicosapentaenoic acid or docosahexaenoic acid-conjugated polycationic carrier
US5626845A (en) * 1995-01-23 1997-05-06 Xenotech Incorporated Method to ameliorate osteolysis and metastasis
US6015555A (en) * 1995-05-19 2000-01-18 Alkermes, Inc. Transferrin receptor specific antibody-neuropharmaceutical or diagnostic agent conjugates
US5833987A (en) * 1995-06-07 1998-11-10 Trustees Of Dartmouth College Treatment of T cell mediated autoimmune disorders
US6001358A (en) * 1995-11-07 1999-12-14 Idec Pharmaceuticals Corporation Humanized antibodies to human gp39, compositions containing thereof
US6042826A (en) * 1996-11-15 2000-03-28 Health Research, Inc. Method for inducing apoptosis of primary central nervous system B cell lymphomas
EP1112084B2 (en) * 1998-08-11 2012-04-25 Biogen Idec Inc. Combination therapies for b-cell lymphomas comprising administration of anti-cd20 antibody

Also Published As

Publication number Publication date
US20020009444A1 (en) 2002-01-24
AU2001259142C1 (en) 2006-11-23
MXPA02010507A (es) 2003-05-14
AU5914201A (en) 2001-11-07
EP1286692A1 (en) 2003-03-05
ZA200208627B (en) 2003-08-11
CA2405632A1 (en) 2001-11-01
EP1286692A4 (en) 2004-11-17
AU2001259142B2 (en) 2006-03-09
CN101130078A (zh) 2008-02-27
KR20030016250A (ko) 2003-02-26
CN1437478A (zh) 2003-08-20
WO2001080884A1 (en) 2001-11-01
JP2003531178A (ja) 2003-10-21

Similar Documents

Publication Publication Date Title
BR0110364A (pt) Administração intratecal de rituximab para tratamento de linfomas do sistema nervoso central
IL267381A (en) A pharmaceutical preparation containing dextromethorphan and quinidine for the treatment of nervous disorders
HK1245320A1 (zh) 治療缺陷α半乳糖苷酶A的藥物製劑
BR0109705A (pt) Uso combinado de anticorpos ou antagonistas anti-citocina e anticd20 para o tratamento de linfoma de célula b
BRPI0516531A (pt) imunoterapia de distúrbios auto-imunes
TW200617013A (en) Diazabicyclic central nervous system active agents
SG146653A1 (en) Methods and reagents for the treatment of immunoinflammatory disorders
GB9306578D0 (en) Therapeutic agents
PH31335A (en) Naphthalamides as central nervous system agent.
EP1556068A4 (en) TREATMENT OF AUTISM AND SIMULTANEOUS DISEASES
Dell'Osso et al. Diagnosis and treatment of obsessive‐compulsive disorder and related disorders
BR9808606A (pt) Materiais e métodos para tratamento de doenças com ribozimas
Oshima et al. One‐year low‐dose valacyclovir as prophylaxis for varicella zoster virus disease after allogeneic hematopoietic stem cell transplantation. A prospective study of the Japan Hematology and Oncology Clinical Study Group
IL121272A (en) Pharmaceutical compositions comprising adenosine and their use for treating or preventing leukopenia
PT994875E (pt) Derivados de 3-piridil-1-aza-biciclo-alcano para a prevencao e tratamento de desordens do snc
BR0115364A (pt) Tratamento de disfunção sexual
Canuso et al. Does minimizing neuroleptic dosage influence hyponatremia?
Millot et al. Successful second allogeneic stem cell transplantation in second remission induced by dasatinib in a child with Philadelphia chromosome positive acute lymphoblastic leukemia
BRPI0409683A (pt) 5-hidroxiindóis com grupos n-óxido e seu emprego como agentes terapêuticos
CY1108050T1 (el) Η χρηση της μεκαμυλαμινης για τη θεραπεια των ανταποκρινομενων στη νικοτινη νευροψυχιατρικων διαταραχων
Nishikawa et al. Combined treatment of tardive dyskinesia with clonidine and neuroleptics: a follow-up study of three cases for three years
Eapen et al. Comorbid obsessive-compulsive disorder and Tourette syndrome: therapeutic interventions
Friedberg Overcoming rituximab resistance: The US clinical experience with bendamustine
Johnson Characterization of the role of serotonin receptor subtypes (5-HT1 and 5-HT2) and nitric oxide in guinea pig dural plasma protein extravasation
Bhatia et al. Role of fentanyl and diazepam premedication in prevention of untoward reactions of etomidate.

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 10A ANUIDADE(S).

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2144 DE 07/02/2012.